Gerlach J, Christensen J K, Christensen T L, Elley J, Jensen J P, Larsen S B
Sct. Hans Hospital, Department 2, Roskilde, Denmark.
Psychopharmacology (Berl). 1987;93(3):296-300. doi: 10.1007/BF00187246.
Suriclone is a new anxiolytic drug belonging to the family of cyclopyrrolones. Although chemically entirely different from the benzodiazepines, it acts as a benzodiazepine agonist with very high affinity for the benzodiazepine receptors. In the present cross-over study, 33 out-patients with a diagnosis of neurotic anxiety were treated with suriclone (mean dose 2 mg/day) and diazepam (25 mg/day) in two 6-week periods. Both drugs had a significant anxiolytic effect, but diazepam appeared to have a better effect within the first 2 weeks of treatment, while no significant difference was seen after treatment, while no significant difference was seen after treatment for 6 weeks. Suriclone and diazepam had a different side effect profile: suriclone produced mainly dizziness, while diazepam caused sedation. This may reflect the fact that suriclone and benzodiazepines bind to distinct sites or different allosteric conformations of the benzodiazepine receptors.
舒立克隆是一种新型抗焦虑药物，属于环吡咯酮类。尽管其化学结构与苯二氮䓬类完全不同，但它作为苯二氮䓬类激动剂，对苯二氮䓬受体具有非常高的亲和力。在本交叉研究中，33例诊断为神经症性焦虑的门诊患者在两个6周疗程中分别接受舒立克隆（平均剂量2毫克/天）和地西泮（25毫克/天）治疗。两种药物均有显著的抗焦虑作用，但地西泮在治疗的前2周似乎效果更好，而治疗6周后未见显著差异。舒立克隆和地西泮有不同的副作用谱：舒立克隆主要产生头晕，而地西泮导致镇静。这可能反映了舒立克隆和苯二氮䓬类与苯二氮䓬受体的不同位点或不同变构构象结合的事实。
